Depression anxiety with, treatment

Ciraulo DA, Jaffe JH Tricyclic antidepressants in the treatment of depression associated with alcoholism. Clin Psychopharmacol 1 146—150, 1981 Ciraulo DA, Nace E Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. Am J Addict 9 276—284, 2000 Ciraulo DA, Barnhill JG, Jaffe JH, et al Intravenous pharmacokinetics of 2-hydroxy-imipramine in alcoholics and normal controls. J StudAlcohol 51 366-372, 1990 Ciraulo DA, Knapp CM, LoCastro J, et al A benzodiazepine mood effect scale reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 27 339—347, 2001 Collins MA Tetrahydropapaveroline in Parkinson s disease and alcoholism a look back in honor of Merton Sandler. Neurotoxicology 25 117-120, 2004 COMBINE Study Research Group Testing combined pharmacotherapies and behavioral interventions in alcohol dependence rationale and methods. Alcohol Clin Exp Res 27 1107-1122, 2003a... 

Evaluate the clinical outcomes of treatment by using the UPDRS. In addition, periodically ask patients to record the amount of on and off time they have with and without dyskinesias in a diary. There are a variety of scales that can be used to assess QOL, depression, anxiety, and sleep disorders. Patients with PD cannot be cured but treatment can delay the progression of symptoms and improve QOL. Delaying the patient s admission into a nursing home is a good outcome. 

Venlafaxine extended release, in doses of 75 to 225 mg/day, improves social anxiety, performance, and avoidance behavior with a reduction in disability.61 Treatment with venlafaxine results in response rates similar to those seen with paroxetine.60 Venlafaxine may be effective in SSRI non-responders.62 As with SSRIs, doses should be tapered slowly when discontinuing therapy. Tolerability is similar to that observed in depression trials with venlafaxine extended release. Common side effects are anorexia, dry mouth, nausea, insomnia, and sexual dysfunction. 

Schneier, F. R., Blanco, C., Campeas, R., Lewis-Fernandez, R. el al. (2003). Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety, 17, 191-6. 

Nefazodone is approved for treatment of major depression and appears particularly effective iu treatiug depressed patieuts with agitation or anxiety. Its role in treating anxiety disorders is being studied. 

Generalized Sociai Anxiety Disorder, Treatment Resistance. A significant minority of patients will not experience a satisfactory treatment response to antidepressant therapy, even after a trial of adequate duration at full strength doses. For those with comorbid depression who are experiencing no benefit from SSRI treatment for either the anxiety or depression, then switching treatment is advisable. The options include switching to another SSRI, a SNRI (venlafaxine or perhaps dulox-etine), or, when other alternatives fail, phenelzine. 

Psychiatric medications do not currently play a prominent role in the treatment of cocaine-dependent patients (see Table 6.4). Although researchers have labored to find medications to treat cocaine addiction, there have not been any notable breakthroughs. As with other substance use disorders, the presence of a psychiatric disorder for which medication is indicated (i.e., depression, anxiety disorders, bipolar affective disorder, or schizophrenia) should prompt appropriate treatment. Similar to the presence of alcohol intoxication, deferring a diagnosis for a day or two in a new patient with no past history is often the more prudent course. 

For the treatment of psychoneurotic patients with depression or anxiety depression or anxiety associated with alcoholism or organic disease psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. 

A considerable number of tricyclic antidepressants have been developed in the past, although with slight differences in their pharmacological activities, ah with similar efficacy. They are primarily indicated for the treatment of endogenous depression. However this does not exclude efficacy in patients in whom the depression is associated with organic disease or in patients with reactive depression or depression combined with anxiety. They may also benefit patients during the depressive phase of manic-depressive disorder. For some also efficacy has been claimed in panic states, phobic disorders, and in obsessive-compulsive disorders. 

Extensive sleep studies have been conducted with a variety of sedative-hypnotic drugs, and all of these drugs appear to alter the normal distribution of rapid eye movement (REM) and non-REM sleep. Most of the older sedative-hypnotic agents markedly depress REM sleep. In contrast, when the benzodiazepines are used in appropriate doses, they depress REM sleep to a much smaller extent. As with treatment of anxiety, the choice... 

Tranylcypromine ( rans-2-phenylcyclopropylamine, TCP, 8a) has close structural similarity to amphetamine (2-amino-1-phenylpropane) and is known as a nonhydrazine, nonselective, and irreversible inhibitor of both MAO A and B. It is also a potent reversible inhibitor of CAOs [36,37], Tranylcypromine has an important clinical use for treatment of certain depressive illnesses, particularly of nonendo-genous and atypical depressions and depressions associated with anxiety, agitation, phobias, and anergia [38-40], In combination with lithium, it is also applied for treatment of refractory depression [41], Recent reports also discussed MAO inhibitors as useful agents against neurodegenerative disorders such as Parkinson s or Alzheimer s diseases [42], Despite impressive clinical successes, clinical use of tranylcypromine and other MAO inhibitors is limited by various problems, including the cheese effect discussed in Section 1,... 

Clinicians should be aware that many of their patients may be taking alternative treatments either via self-care or prescribed by CAM practitioners. Inquiring about this should be routine because of potential side effects and drug interactions. A working knowledge of CAM treatments will allow child psychiatrists to give parents and patients advice about safety and effectiveness. Use of St. John s wort in children with unipolar depression may at times be appropriate, particularly in cases where more standard treatments are contraindicated or have failed. However, it should be used cautiously and with an appropriate explanation of its risks and benefits, as a competent clinician would do for any treatment. Use of St. John s wort for other conditions is not currently recommended given the lack of evidence for efficacy. Kava extracts may be used for anxiety, with similar provisos. There are much fewer data about the efficacy and safety of other dietary supplements and their use cannot be supported at this point. 

Cognitive psychotherapeutic techniques have further been developed since their introduction by Beck et al. (1979), who demonstrated their effectiveness in the treatment of depression. Several studies have extended Beck s cognitive therapy to adulthood schizophrenia with encouraging clinical results. The efficacy of cognitive-behavioral approaches could be demonstrated in several key areas in schizophrenia, especially therapy-resistant hallucinations and delusions. Several approaches have also addressed therapeutic efforts in the treatment of associated symptoms such as anxiety and depression. In addition, cognitive-behavioral techniques have been shown to be effective in treatment of chronic schizophrenia, resulting in reduction of distress and disruption due to hallucinations and delusions. In some studies anxiety and depression associated with schizophrenia could also be reduced to some extent. The value of these techniques in children and adolescents has yet to be demonstrated. 

SRls are currently the most prevalent pharmacological treatment used for panic disorder [see Westenberg and Den Boer, Chapter 24, in this volume], even though tricyclic antidepressants, monoamine oxidase inhibitors [MAOls], and benzodiazepines are also effective. The efficacy of the SRI antidepressants and the observation that initially they may induce deterioration of symptoms [which is usually not the case with treatment of depressed patients with the same medications] raise issues related to the pathobiology of anxiety and its comorbidity with depression. 

Brown RG, Marsden CD Cognitive function in Parkinson s disease from description to theory. Trends Neurosci 13 21-29, 1990 Brown RG, Marsden CD Dual task performance and processing resources in normal subjects and patients with Parkinson s disease. Brain 114 215-231, 1991 Brown RP, Frances A, Kocsis JH, et al Psychotic vs. nonpsychotic depression comparison of treatment response. J Nerv Ment Dis 170 635-637, 1982 Brown SA, Irwin M, Schuckit MA Changes in anxiety among abstinent male alcoholics. J Stud Alcohol 52 55-61, 1991... 

Hamilton M, White J Factors related to the outcome of depression treated with ECT. Journal of Mental Science 106 1031-1041, 1960 Hammarback S, Backstrom T Induced anovulation as treatment of premenstrual tension syndrome a double-bhnd crossover study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67 159-166, 1988 Hamon M Neuropharmacology of anxiety-perspectives and prospects. Trends Pharmacol Sci 15(2 36-39, 1994... 

Schatzberg and Cole (204) reviewed 20 controlled studies of BZDs used in the treatment of a mixed profile of depressions and also concluded that, although anxiety and insomnia may be significantly relieved, core depressive symptoms (e.g., psychomotor retardation and diurnal variation) remain essentially unchanged. Some positive resolutions were seen in depressions associated with a high level of anxiety, but there was little evidence for efficacy in more severe depressions without prominent anxiety. 

BZDs may exacerbate depression and possibly increase suicide risk. Case reports and clinical trials also indicate that BZD treatment of generalized anxiety and panic may result in emergence of depression (215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225 and 226). In some of these reports, depression is ill-defined, but in others, it met DSM-III criteria for a major depressive disorder, requiring treatment with an antidepressant ( 225, 226). Depression has been reported with a variety of BZDs (alprazolam, bromazepam, clonazepam, diazepam, lorazepam), but there is no evidence that one is more likely than another to cause or aggravate depressive illness. 

The role of medication in the treatment of bulimia nervosa seems better established than its role in the treatment of anorexia nervosa. The American Psychiatric Association Practice Guideline for Eating Disorders ( 510) suggests that antidepressants may be useful in bulimia nervosa with or without depression. They may be particularly helpful, however, in those with depression, anxiety, obsessions, or who have failed psychosocial therapies. 

Other bad news in the treatment of depression is that many responders never remit (Table 5 — 17). In feet, some studies suggest that up to half of patients who respond nevertheless fail to attain remission, including those with either apathetic responses" or anxious responses (Table 5 — 18). The apathetic responder is one who experiences improved mood with treatment, but has continuing lack of pleasure (anhedonia), decreased libido, lack of energy, and no zest. The anxious responder, on the other hand, is one who had anxiety mixed with depression and who experiences improved mood with treatment but has continuing anxiety, especially generalized anxiety characterized by excessive worry, plus insomnia and somatic symptoms. Both types of responders are better, but neither is well. 

Generalized anxiety disorder is more likely to remit spontaneously or with treatment than is major depressive disorder. 

---